Please enable Javascript
ASH 2021 Multiple Myeloma News
iStopMM Study: Population-Based Prevalence of Smoldering Multiple Myeloma
Ariel Jones
Conferences
|
December 17, 2021
This marks the first time a study identified epidemiological and clinical characteristics of SMM in a general population.
Read More
Daratumumab-Based Triplet Regimen in Real-World Patients With Relapsed or Refractory Multiple Myeloma
Ariel Jones
Conferences
|
December 17, 2021
Researchers evaluated real-world data on DVd for treatment of patients with relapsed or refractory multiple myeloma.
Read More
Multiple Myeloma and Waldenström Macroglobulinemia Patients Have Impaired COVID-19 Vaccine Responsiveness
Ariel Jones
Conferences
|
December 11, 2021
Both are malignancies associated with significant immunoparesis.
Read More
Utility of IMWG Frailty Scoring in Patients With Relapsed/Refractory Multiple Myeloma
Ariel Jones
Conferences
|
December 11, 2021
Fabio Efficace, PhD, and a team of researchers investigated IMWG frailty scoring in patients with previously treated disease.
Read More
Results from the iStopMM Study Suggest MGUS Screening Enables Early Detection and Intervention
Ariel Jones
Conferences
|
December 11, 2021
Researchers explored whether screening for MGUS could increase the frequency of patients with MM being diagnosed.
Read More
Isatuximab Plus RVd Produces Better MRD Negativity Rates Than RVd Alone
Ariel Jones
Conferences
|
December 11, 2021
This is according to findings from a phase III study presented during the 2021 ASH Annual Meeting.
Read More
Daratumumab Combination Leads to Deep Durable Response in Transplant-Eligible Myeloma
Ariel Jones
Conferences
|
December 10, 2021
The findings report results from 24 months of maintenance therapy and were presented at the ASH Annual Meeting 2021.
Read More
Research Shows Promising Efficacy of bb21217 in Relapsed/Refractory Myeloma
Ariel Jones
Conferences
|
December 10, 2021
Updates from this trial were presented at the 63rd American Society of Hematology Annual Meeting & Exhibition.
Read More
Advertisement
Advertisement